

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant(s): Feige, et al.

Serial No.: 10/609,217

Filed: June 27, 2003

For: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.: A-527B



Group Art Unit No.: 1646

Examiner:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form for consideration by the Examiner.

The supplemental information disclosure statement submitted herewith is being filed before the mailing of a first Office Action on the merits.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,



Timothy J. Gaul
Attorney/Agent for Applicants
Registration No.: 33,111
Phone: (805) 447-2688
Date: February 21, 2006


Please send all future correspondence to:
US Patent Operations/TJG
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE"Express Mail" mail labeling number: EL 732696710 USDate of Deposit: February 21, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SHERY ST. ANDREW
Printed Name


Signature



Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket #	A-527B	Serial No.	10/609.217
	Applicant Feige et al			
	Filing Date	June 27, 2003	Group	1646

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

EXAMINER'S
INITIALS**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

		Abstract # 4261. Blood, Volume 106, Issue 11, November 16, 2005. Title: Pharmacokinetics and Pharmacodynamics of CNTO 528, a Novel Erythropoietin Receptor Agonist in Normal and Anemic Rats. Authors: Peter Bugelski et al. Page 1 of 1
		Abstract #4283. Blood, Volume 106, Issue 11, November 16, 2005. Title: A Phase 1, Single and Fractionated, Ascending Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of an Erythropoietic Mimetic Antibody Fusion Protein, CNTO528 in Healthy Male Subjects. Authors: K.L. Franson et al. Page 1 of 1

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.